SCHEMBL18201265

SCHEMBL18201265

c1ccc2c(-c3cnc(-c4nc5ccccc5c5c4ccc4ccccc45)nc3)cccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
RECQL P46063 1/20 0.43
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18201308 0.93 MAPT (0.40) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18201176 0.91 CYP3A4 (0.43) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18200678 0.89 NPC1 (0.50) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18200710 0.89 NPC1 (0.49) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18201166 0.88 CYP1A2 (0.51) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18200711 0.85 MAPT (0.45) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18200864 0.85 MEN1 (0.39) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18201303 0.84 MAPT (0.40) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18201305 0.84 MEN1 (0.45) MAPTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL18200646 0.84 ENPP3 (0.41) MAPTCA12CA9KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 MAPT 1937/4885SMN1; SMN2 3944/4885RAB9A 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.